S

hares of Spectrum Pharmaceuticals (SPPI) jumped 36 percent Wednesday on excitement generated by its experimental lung cancer drug poziotinib. With the surge, the company’s market value is now approaching $2 billion.

Justified? Maybe, but only if you’re making optimistic assumptions based on very preliminary clinical data. And only if you’re willing to forget that Spectrum isn’t very good at either developing or selling cancer drugs.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.